Nasus Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of September 2025 for Nasus Pharma Ltd., a foreign private issuer headquartered in Tel Aviv, Israel. The report details corporate governance changes approved by the Board of Directors on September 3, 2025.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance updates and contains no financial performance data.
Material Changes
- Board Appointment: Dan Teleman, the Company's Chief Executive Officer, was appointed as a director to fill a vacancy. He will serve as a Class III director with a term expiring at the 2028 annual general meeting.
- Committee Change: The Board resolved to replace David Silberman with Ronnie Hershman as a member of the Compensation Committee.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirm the effective date of Dan Teleman's dual role as CEO and Board Director.
- Verify the composition of the Compensation Committee following the appointment of Ronnie Hershman.
- Review the Company's Articles of Association regarding the process for filling Board vacancies.